What is the current market size and future outlook for the neurofibromatosis type 1 market?
The neurofibromatosis type 1 (NF1) market size has grown strongly in recent years. It will grow from $8.06 billion in 2024 to $8.86 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to increasing awareness, rise in healthcare expenditure, population growth, favorable government policies, and modernization in medical infrastructure.
The neurofibromatosis type 1 (NF1) market size is expected to see strong growth in the next few years. It will grow to $12.77 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to rising cases of blood cancer, increasing incidence of plexiform tumors, prevalence of nerve sheath tumors, rising incidence of neurofibromatosis, and increasing adoptions of neurofibromatosis therapeutics. Major trends in the forecast period include research and development, development of novel therapies, improvements in diagnostic methods, tumor specific therapeutics, and development of new drugs.
Get Your Free Sample of The Global Neurofibromatosis Type 1 Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21230&type=smp
How has the neurofibromatosis type 1 market evolved, and what factors have shaped its growth?
The spontaneous (de novo) mutation is expected to propel the growth of the neurofibromatosis type 1 (NF1) market going forward. Spontaneous (de novo) mutation refers to a genetic alteration that arises for the first time in an individual due to errors in DNA replication or environmental factors, rather than being inherited from parents. Rising spontaneous (de novo) mutation is attributed to increased parental age, environmental factors such as radiation and chemical exposure, and errors in DNA replication during cell division. Neurofibromatosis type 1 (NF1) contributes to spontaneous (de novo) mutations due to its high mutation rate in the NF1 gene, which frequently undergoes large deletions, insertions, or point mutations during gametogenesis, leading to new cases without a family history. For instance, in August 2023, according to the report published by Molecular Biology and Evolution, a US-based peer-reviewed journal, a total of 1.17 million autosomal and pseudoautosomal variants, averaging 11,007 variants per offspring, passed the Mendelian violation filter. Among these, 534 putative de novo mutations (DNMs) were identified in POR and TVA families, excluding those shared among siblings. Therefore, the spontaneous (de novo) mutation is driving the growth of the neurofibromatosis type 1 (NF1) market.
What are the major segments of the neurofibromatosis type 1 market?
The neurofibromatosis type 1 market covered in this report is segmented –
1) By Treatment: Medication, Surgery, Radiation Therapy, Other Treatments
2) By Disease Type: Plexiform Neurofibromas, Cutaneous Neurofibromas, Optic Gliomas, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End Users: Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Medication: Targeted Therapy, Pain Management Medications, Anticonvulsants
2) By Surgery: Tumor Removal Surgery, Nerve Decompression Surgery
3) By Radiation Therapy: Stereotactic Radiosurgery, External Beam Radiation Therapy
4) By Other Treatments: Physical Therapy, Genetic Counseling, Psychological Support And Counseling
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/neurofibromatosis-type-1-global-market-report
Which companies dominate the neurofibromatosis type 1 market?
Major companies operating in the neurofibromatosis type 1 market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Shanghai Fosun Pharmaceutical (Group) Co. Ltd, BeiGene Ltd., BioMarin Pharmaceutical Inc, Exelixis Inc., Blueprint Medicines Corporation, SpringWorks Therapeutics Inc, Onclive LLC, Healx Limited, Infixion Bioscience Limited, NFlection Therapeutics Inc, Pasithea Therapeutics Corporation, Mulberry Biotherapeutics Inc.
How will evolving trends contribute to the growth of the neurofibromatosis type 1 market?
Major companies operating in the neurofibromatosis type 1 (NF1) market are focusing on introducing innovative products such as kinase inhibitor to improve targeted treatment and patient outcomes. A kinase inhibitor refers to a type of drug that blocks the activity of kinases, which are enzymes responsible for transferring phosphate groups to proteins, thereby regulating various cellular processes. For instance, in May 2023, AstraZeneca plc, a UK-based pharmaceutical industry company, received approval from China for Koselugo (selumetinib), treating symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged three years and above who have neurofibromatosis type 1 (NF1). This approval expands the availability of targeted treatment options for pediatric NF1 patients, enhancing disease management and improving quality of life. The introduction of Koselugo (selumetinib) in China aligns with the growing focus on precision medicine, offering a non-surgical alternative for managing inoperable plexiform neurofibromas.
What are the key regional dynamics of the neurofibromatosis type 1 market, and which region leads in market share?
North America was the largest region in the neurofibromatosis type 1 (NF1) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurofibromatosis type 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Neurofibromatosis Type 1 Market Report 2025 Offer?
The neurofibromatosis type 1 market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Neurofibromatosis type 1 (NF1) is a genetic disorder that primarily affects the nervous system, causing the growth of benign tumors along nerves in the skin, brain, and other parts of the body. It is caused by mutations in the NF1 gene, leading to neurofibromin deficiency, a protein that helps regulate cell growth. This results in various symptoms, including café-au-lait spots (light brown skin patches), freckling in unusual areas, learning disabilities, skeletal abnormalities, and, in some cases, vision or nerve-related complications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21230
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
